Duke University to assess probiotics in COVID-19 exposure

Culturelle® is a leading probiotic brand focused on supporting the digestive and immune health of families worldwide.

Duke University Health System’s Institutional Review Board approved a randomized, double blind, placebo-controlled clinical trial of the probiotic Lactobacillus rhamnosus GG in COVID-19 exposed households. 

Culturelle^® is the only commercially available brand in the U.S. with 100% Lactobacillus rhamnosus GG products, and i-Health, Inc., marketer of Culturelle^®, will be providing support for the trial. 

Culturelle^® is a leading probiotic brand focused on supporting the digestive and immune health of families worldwide. Its portfolio of products covers the needs of families from infants to adults. Using only ingredients that pass the highest standards of testing, Culturelle^® products contain probiotic strains that have been thoroughly researched, such as Lactobacillus rhamnosus GG, which has over 30 years of scientific research and over 200 clinical studies.

“Our mission is finding new ways to enhance the health and wellness of people around the world,” says Jane Wadler, Global SVP of Marketing at i-Health, Inc. “And with the current public health threat, that mission is intensified. We wholeheartedly applaud and support Dr. Wischmeyer’s and Dr. Sung’s efforts to better protect those most vulnerable to the risk of COVID-19 and investigate Lactobacillus rhamnosus GG as a potential solution. We are happy to provide clinical supplies for the trial as well as needed financial support to get it off the ground.”